Advertisement

Use of Resource Modeling to Quantify the Organizational Impact of Subcutaneous Formulations for the Treatment of Oncologic Patients: The Case of Daratumumab in Multiple Myeloma

      Abstract

      Purpose

      Resource modeling aims to explicitly quantify the effects of adopting new health care technologies in settings with capacity-related constraints. The aim of this analysis was to use resource modeling to explore the effects of the uptake of first-line treatment with daratumumab on wait lists and wait times in patients with untreated multiple myeloma. Two formulations were compared: the standard IV formulation (DARA-IV) and a recently approved SC formulation (DARA-SC).

      Methods

      First, semi-structured interviews at six oncologic centers were used to retrieve data on the management of patients given a DARA-IV regimen. Second, a discrete event simulation (DES) model was built to estimate the effects on resource consumption, wait lists, and wait times in scenarios with different incident numbers of patients treated with either DARA-IV or DARA-SC.

      Findings

      In all of the simulated scenarios with more incident patients initiated on first-line treatment with DARA-IV, the actual capacity of infusion chairs was not enough to meet the demand, leading to increases in wait times and wait lists. In the highest-demand scenario, 17 more infusion chairs per center would be required to avoid such increases. Treatment with DARA-SC would allow centers to meet the demand with their actual capacity.

      Implications

      DES modeling can effectively be used to formally explore the effects of different formulations on the use of limited resources, wait lists, and wait times at the facility level. Based on the findings from this analysis, DARA-SC may free up resources and prevent short- and long-term costs to infusion centers.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Marshall DA
        • Burgos-Liz L
        • Ijzerman MJ
        • Osgood ND
        • Padula WV
        • Higashi MK
        • et al.
        Applying dynamic simulation modeling methods in health care delivery research—the SIMULATE checklist: report of the ISPOR simulation modeling emerging good practices task force.
        Value Health J Int Soc Pharmacoeconomics Outcomes Res. 2015; 18: 5-16
      1. HTA Core Model [EuNetHTA website]. Available at: https://www.eunethta.eu/hta-core-model, approximately May 2021.

        • Thokala P
        • Dixon S
        • Jahn B.
        Resource modelling: the missing piece of the HTA jigsaw?.
        PharmacoEconomics. 2015; 33: 193-203
        • Stahl JE
        • Sandberg WS
        • Daily B
        • Wiklund R
        • Egan MT
        • Goldman JM
        • et al.
        Reorganizing patient care and workflow in the operating room: a cost-effectiveness study.
        Surgery. 2006; 139: 717-728
        • Jahn B
        • Pfeiffer KP
        • Theurl E
        • Tarride JE
        • Goeree R.
        Capacity constraints and cost-effectiveness: a discrete event simulation for drug-eluting stents.
        Med Decis Making. 2010; 30: 16-28
        • Standfield L
        • Comans T
        • Raymer M
        • O'Leary S
        • Moretto N
        • Scuffham P
        The efficiency of increasing the capacity of physiotherapy screening clinics or traditional medical services to address unmet demand in orthopaedic outpatients: a practical application of discrete event simulation with dynamic queuing.
        Appl Health Econ Health Policy. 2016; 14: 479-491
        • Salleh S
        • Thokala P
        • Brennan A
        • Hughes R
        • Dixon S.
        Discrete event simulation-based resource modelling in health technology assessment.
        PharmacoEconomics. 2017; 35: 989-1006
        • Marshall DA
        • Burgos-Liz L
        • IJzerman MJ
        • Crown W
        • Padula WV
        • Wong PK
        • et al.
        Selecting a dynamic simulation modeling method for health care delivery research-part 2: report of the ISPOR Dynamic Simulation Modeling Emerging Good Practices Task Force.
        Value Health J Int Soc Pharmacoeconomics Outcomes Res. 2015; 18: 147-160
        • Karnon J
        • Stahl J
        • Brennan A
        • Caro JJ
        • Mar J
        • Möller J
        • et al.
        Modeling using discrete event simulation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force–4.
        Value Health J Int Soc Pharmacoeconomics Outcomes Res. 2012; 15: 821-827
        • Standfield LB
        • Comans TA
        • Scuffham PA.
        An empirical comparison of Markov cohort modeling and discrete event simulation in a capacity-constrained health care setting.
        Eur J Health Econ HEPAC Health Econ Prev Care. 2017; 18: 33-47
        • Batu ED
        • Lamot L
        • Sag E
        • Ozen S
        • Uziel Y.
        How the COVID-19 pandemic has influenced pediatric rheumatology practice: results of a global, cross-sectional, online survey.
        Semin Arthritis Rheum. 2020; 50: 1262-1268
        • Elfalah M
        • Airyalat SA
        • Toro MD
        • Rejdak R
        • Zweifel S
        • Nazzal R
        • et al.
        Delayed intravitreal anti-VEGF therapy for patients during the COVID-19 lockdown: an ethical endeavor.
        Clin Ophthalmol Auckl NZ. 2021; 15: 661-669
        • Akula SM
        • Abrams SL
        • Steelman LS
        • Candido S
        • Libra M
        • Lerpiriyapong K
        • et al.
        Cancer therapy and treatments during COVID-19 era.
        Adv Biol Regul. 2020; 77100739
        • Usmani SZ
        • Nahi H
        • Plesner T
        • Weiss BM
        • Bahlis NJ
        • Belch A
        • et al.
        Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials.
        Lancet Haematol. 2020; 7: e447-e455
        • Facon T
        • Kumar S
        • Plesner T
        • Orlowski RZ
        • Moreau P
        • Bahlis N
        • et al.
        Daratumumab plus lenalidomide and dexamethasone for untreated myeloma.
        N Engl J Med. 2019; 380: 2104-2115
        • Mateos MV
        • Dimopoulos MA
        • Cavo M
        • Suzuki K
        • Jakubowiak A
        • Knop S
        • et al.
        Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma.
        N Engl J Med. 2018; 378: 518-528
        • Moreau P
        • Attal M
        • Hulin C
        • Arnulf B
        • Belhadj K
        • Benboubker L
        • et al.
        Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.
        Lancet. 2019; 394: 29-38
        • Mateos MV
        • Nahi H
        • Legiec W
        • Grosicki S
        • Vorobyev V
        • Spicka I
        • et al.
        Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial.
        Lancet Haematol. 2020; 7: e370-e380
        • Chari A
        • Rodriguez-Otero P
        • McCarthy H
        • Suzuki K
        • Hungria V
        • Sureda Balari A
        • et al.
        Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study.
        Br J Haematol. 2021; 192: 869-878
        • Ghetti G
        • Pradelli L
        • Crovato E
        • Bellucci S.
        POSB72 Subcutaneous daratumumab in the treatment of multiple myeloma in Italy: a budget impact analysis.
        Value Health. 2022; 25: S74
        • Toro-Diaz H
        • Li S
        • Morano R
        • Tambour M
        • Dansk V
        • Lam A
        • et al.
        PCN82 budget impact analysis of subcutaneous daratumumab for the treatment of patients with multiple myeloma in Sweden.
        Value Health. 2020; 23: S436
      2. Daratumumab [product information] [European Medicines Agency website]. Available at: https://www.ema.europa.eu/en/documents/product-information/darzalex-epar-product-information_it.pdf, approximately May 2021.

      3. Kumar K, Facon T, Usmani S, Plesner T, Orlowski Z, Touzeau C, et al. Updated analysis of daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) in patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM): the phase 3 Maia study [Blood online]. Available at: https://ash.confex.com/ash/2020/webprogram/Paper134847.html, approximately May 2021.

        • Bhattacharya R
        • Herren K
        • Poonawalla I
        • Bunniran S
        • Bloomfield A
        • Schwab P.
        Comparing medical utilization and cost outcomes in oral versus injectable immunotherapy users with chronic inflammatory joint and skin diseases.
        J Manag Care Spec Pharm. 2020; 26: 1246-1256
        • Freeman L
        • Kee A
        • Tian M
        • Mehta R.
        Evaluating treatment patterns, relapses, healthcare resource utilization, and costs associated with disease-modifying treatments for multiple sclerosis in DMT-naïve patients.
        Clin Outcomes Res. 2021; 13: 65-75
        • Franken MG
        • Kanters TA
        • Coenen JL
        • de Jong P
        • Koene HR
        • Lugtenburg PJ
        • et al.
        Potential cost savings owing to the route of administration of oncology drugs: a microcosting study of intravenous and subcutaneous administration of trastuzumab and rituximab in the Netherlands.
        Anticancer Drugs. 2018; 29: 791-801
        • O'Brien GL
        • O'Mahony C
        • Cooke K
        • Kinneally A
        • Sinnott SJ
        • Walshe V
        • et al.
        Cost minimization analysis of intravenous or subcutaneous trastuzumab treatment in patients with HER2-positive breast cancer in Ireland.
        Clin Breast Cancer. 2019; 19: e440-e451